Bispecific antibodies enhance tumor‐infiltrating T cell cytotoxicity against autologous HER‐2‐expressing high‐grade ovarian tumors-Reference-Cited by-同舟云学术

Bispecific antibodies enhance tumor‐infiltrating T cell cytotoxicity against autologous HER‐2‐expressing high‐grade ovarian tumors

Published:2019-12-13 Issue:6 Volume:107 Page:1081-1095
ISSN:0741-5400
Container-title:Journal of Leukocyte Biology
language:en
Short-container-title:J Leukoc Biol

Author:

Oberg Hans‐Heinrich¹,Janitschke Lisa¹,Sulaj Vjola¹,Weimer Jörg²,Gonnermann Daniel¹,Hedemann Nina²,Arnold Norbert²³,Kabelitz Dieter¹,Peipp Matthias⁴,Bauerschlag Dirk²,Wesch Daniela¹

Affiliation:

1. Institute of Immunology Christian‐Albrechts University of Kiel Kiel Germany

2. Department of Gynecology and Obstetrics UKSH Campus Kiel Kiel Germany

3. Institute of Clinical Molecular Biology UKSH CAU Kiel Kiel Germany

4. Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II UKSH CAU Kiel Kiel Germany

Funder

California Department of Fish and Game

Publisher

Wiley

Subject

Cell Biology,Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/JLB.5MA1119-265R

Reference47 articles.

1. Cancer statistics, 2019

2. Tumor microenvironment: The culprit for ovarian cancer metastasis?

3. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant

4. Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology Group

5. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements and Challenges in Cancer Immunotherapy;Advances in Medical Diagnosis, Treatment, and Care;2024-08-28

2. Camelid‐derived Tcell engagers harnessing human γδ T cells as promising antitumor immunotherapeutic agents;European Journal of Immunology;2024-05-28

3. Developing innovative strategies of tumor‑infiltrating lymphocyte therapy for tumor treatment;Oncology Reports;2024-04-26

4. New immune cell engagers for cancer immunotherapy;Nature Reviews Immunology;2024-01-25

5. Vdelta1 T cells are more resistant than Vdelta2 T cells to the immunosuppressive properties of galectin-3;Frontiers in Immunology;2024-01-08